Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Assets (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Assets for 16 consecutive years, with $190.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Assets fell 6.15% to $190.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $190.3 million, a 6.15% decrease, with the full-year FY2025 number at $190.3 million, down 6.15% from a year prior.
  • Assets was $190.3 million for Q4 2025 at Anika Therapeutics, roughly flat from $189.4 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $363.1 million in Q2 2021 to a low of $187.7 million in Q2 2025.
  • A 5-year average of $290.2 million and a median of $328.5 million in 2023 define the central range for Assets.
  • Peak YoY movement for Assets: grew 0.46% in 2022, then dropped 29.48% in 2024.
  • Anika Therapeutics' Assets stood at $347.5 million in 2021, then increased by 0.46% to $349.1 million in 2022, then fell by 22.48% to $270.6 million in 2023, then decreased by 25.09% to $202.7 million in 2024, then fell by 6.15% to $190.3 million in 2025.
  • Per Business Quant, the three most recent readings for ANIK's Assets are $190.3 million (Q4 2025), $189.4 million (Q3 2025), and $187.7 million (Q2 2025).